Sheba Healthspan Research Population (SHARP) Trial - Sheba Longevity Center Diagnostic and Intervention Protocol to Lower Biological Age in Older Adults (SHARP)
Sheba Healthspan Research Population (SHARP) Trial
Background: Population aging is accelerating rapidly in Israel and worldwide, necessitating adaptation of the healthcare system and considering new approaches that serve the needs of older adult populations.
Working hypothesis and aims: We hypothesize that a personalized health and behavior intervention program will decrease the biological age as assessed by several biological aging clocks and improve functional and cognitive performance among older adults.
Methods: We propose to conduct a randomized study among healthy community-dwelling elderly subjects (>50 years old). The study will include an extensive aging assessment and imaging protocol (baseline assessment), including comprehensive physical, functional, sensory, cognitive, and mental assessment. Each participant in the intervention group will receive a personalized intervention program based on an integrative systems approach analysis. In addition, a uniquely developed application will track compliance and monitor physiological data through a provided wearable device. The control group will be assessed at baseline without receiving an intervention program. Each participant will visit the center aging after 6 months for a blood test and after 12 months for a second extensive diagnostic protocol, similar to the baseline assessment protocol. About 1,500 subjects will be recruited to participate in the study.
Expected results: Obtaining data at two points will allow us to examine efficiency and compliance with a personalized intervention program based on integrative systems analysis models. We expect biological age, general well-being, and various clinical and psychosocial outcomes in the intervention group will decrease and improve compared to the control group.
Study importance and relevance: The obtained results may help establish evidence-based healthy aging diagnostics protocols and an effective personalized intervention program that might be applied, with proper modifications, to national healthcare organizations for the general older adult population. In addition, to provides a scientific basis on which policymakers and intervention programs can rely to develop national guidelines for promoting extended health.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
The SHARP study is a prospective, 12-month randomized control study on older adults to study the effect of a personalized health and behavioral intervention plan on the biomarkers of aging. Primary outcomes will be measured at baseline, 6, and 12 months (end of study). Secondary outcomes will be measured at baseline and 12 months (end of study). Participants will be randomly assigned to the intervention or control group.
The study participants will visit the Sheba longevity center between three to four times, depending on the assigned trial group (figure 1): baseline evaluation (visit 1), medical summary and intervention plan (according to the study group, visit 2), after six months for a blood sample (visit 3), and a follow-up evaluation after 12 months (visit 4).
The examination visits (visit 1 and visit 4) will include metabolic analysis through blood and sample tests for lipid, immune, hormonal, and vitamin levels, as well as microbiome and proteomics analysis. Physical and imaging assessments will involve bone density, body composition, sensory tests, grip strength, electroencephalogram (EEG), spirometry, Ankle-brachial index (ABI), and various measurements. Women will undergo gynecological exams, and menopause symptoms will be evaluated. Mental and cognitive aspects will cover well-being, depression, anxiety, and cognitive tests, while lifestyle will encompass socio-demographics, medical history, physical activity, diet, and general health status.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: tzipi strauss, MD
- Telefonnummer: 972526664446
- E-Mail: zipora.strauss@sheba.heath.gov.il
Studieren Sie die Kontaktsicherung
- Name: evelyne bischof, MD PhD
- Telefonnummer: 972512504301
- E-Mail: bischofevelyne@gmail.com
Studienorte
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israel, 5220001
- Rekrutierung
- Sheba Medical Center
-
Kontakt:
- Evelyne Bischof, MD PhD
- Telefonnummer: 00972512504301
- E-Mail: bischofevelyne@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Healthy older adults >50 years old men and women
Exclusion Criteria:
- A former diagnostic of a significant cognitive reduction (MoCa score < 24 ).
- Former diagnosis of neurodegenerative disease as Alzheimer's disease, Parkinson's disease, Lewy body dementia.
- Former diagnosis of psychiatric disease.
- In the past two years, underwent chemotherapy or radiation therapy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Schein-Komparator: Kontrollgruppe
|
The control group will be assessed at baseline without receiving an intervention program.
Each participant will visit the center aging after 6 months for a blood test and after 12 months for a second extensive diagnostic protocol, similar to the baseline assessment protocol.
|
|
Experimental: intervention group
a comprehensive assessment result report, which is divided into major areas of health: cardiovascular, lifestyle habits, mental health, cognitive function, sensory health, sleep patterns, metabolic health, physical strength (stamina), women's and men's health, and biological aging; a personalized recommendation program will be tailored to the participant's assessment results.
|
The study will include an extensive aging assessment and imaging protocol (baseline assessment), including comprehensive physical, functional, sensory, cognitive, and mental assessment.
Each participant in the intervention group will receive a personalized intervention program based on an integrative systems approach analysis.
In addition, a uniquely developed application will track compliance and monitor physiological data through a provided wearable device.
Each participant will visit the center aging after 6 months for a blood test and after 12 months for a second extensive diagnostic protocol, similar to the baseline assessment protocol.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Biomarkers of Aging optimization
Zeitfenster: 12 months
|
Epigenetic biological age will be measured using DNA methylation-based aging clocks.
The outcome will be reported as the change in epigenetic biological age, in years, from baseline to 12 months.
|
12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change From Baseline in Blood-Based Biological Age at 12 Months
Zeitfenster: 12 months
|
Blood-based biological age will be calculated from routine laboratory biomarkers using a biological age algorithm.
The outcome will be reported as the change in blood-based biological age, in years, from baseline to 12 months.
|
12 months
|
|
Change From Baseline in Telomere Length at 12 Months
Zeitfenster: 12 months
|
Telomere length will be measured in blood samples. The outcome will be reported as the change in telomere length from baseline to 12 months. Unit of Measure: KiloBase (KB) |
12 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Evelyne Bischof, MD PhD, Sheba Medical Center
- Hauptermittler: Abigail Goshen, PhD, Sheba Medical Center
- Hauptermittler: Tzipi Strauss, MD, Sheba Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 0761-23-SCM
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Gesundes Altern
-
Seoul National University HospitalAbgeschlossenAltern | Photo-AgingKorea, Republik von
-
Seoul National University HospitalAbgeschlossen
-
University of MichiganBausch Health Americas, Inc.Abgeschlossen
Klinische Studien zur healthspan personalized protocol
-
Astrolab bioEPS COMFAMAAbgeschlossen
-
McMaster UniversityAbgeschlossenOsteopenie | Osteoporose, postmenopausalKanada
-
Universidade do Estado do ParáNoch keine RekrutierungLange COVID | Entzündliche Biomarker | Herzfrequenzvariabilität (HRV) | Herzbiomarker
-
Universidad de MurciaAbgeschlossen
-
Universitat Jaume INoch keine RekrutierungAngst | Depressionen, Unipolar | Emotionale Störungen
-
VA Pittsburgh Healthcare SystemRekrutierungAlzheimer ErkrankungVereinigte Staaten
-
Istanbul University - CerrahpasaAbgeschlossen
-
Guangzhou University of Traditional Chinese MedicineUnbekanntUntersuchung des Zusammenhangs zwischen der Einhaltung von HHEP nach ISTIA und Schlaganfallrezidiven oder kardiovaskulären Ereignissen.China
-
Imam Abdulrahman Bin Faisal UniversityAbgeschlossenOsteoporoseSaudi-Arabien
-
WSAUD A/SUniversity of Nottingham; National Institute for Health Research, United KingdomRekrutierungSchwerhörigkeitVereinigtes Königreich